Precigen, Inc. (NASDAQ:PGEN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN) have earned an average rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $8.50.

PGEN has been the topic of several analyst reports. HC Wainwright increased their price target on shares of Precigen from $8.50 to $9.00 and gave the stock a “buy” rating in a research note on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered Precigen from a “hold” rating to a “sell” rating in a report on Saturday, November 15th.

Insider Activity at Precigen

In other news, Director Jeffrey B. Kindler sold 106,837 shares of Precigen stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $3.38, for a total value of $361,109.06. Following the transaction, the director owned 346,070 shares of the company’s stock, valued at $1,169,716.60. This trade represents a 23.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Harry Jr. Thomasian acquired 8,284 shares of Precigen stock in a transaction dated Thursday, September 25th. The stock was purchased at an average price of $3.62 per share, with a total value of $29,988.08. Following the completion of the purchase, the chief financial officer directly owned 465,694 shares of the company’s stock, valued at $1,685,812.28. The trade was a 1.81% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have purchased 13,216 shares of company stock valued at $46,816 and have sold 4,950,320 shares valued at $19,066,904. 47.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new position in Precigen during the 3rd quarter worth $39,000. Russell Investments Group Ltd. acquired a new position in shares of Precigen during the 3rd quarter worth about $41,000. Vontobel Holding Ltd. bought a new stake in Precigen during the 3rd quarter valued at approximately $48,000. CIBC Bancorp USA Inc. acquired a new stake in Precigen in the 3rd quarter valued at approximately $53,000. Finally, Voya Investment Management LLC grew its holdings in Precigen by 142.9% in the 1st quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 21,633 shares during the last quarter. Institutional investors own 33.51% of the company’s stock.

Precigen Stock Up 3.6%

Shares of Precigen stock opened at $4.32 on Monday. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -3.11 and a beta of 1.16. The stock has a 50-day simple moving average of $3.92 and a 200-day simple moving average of $3.06. Precigen has a 52-week low of $0.69 and a 52-week high of $5.22. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.04 and a quick ratio of 3.95.

Precigen (NASDAQ:PGEN) last released its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The firm had revenue of $2.92 million during the quarter, compared to analyst estimates of $0.67 million. Precigen had a positive return on equity of 1,066.10% and a negative net margin of 3,912.92%. On average, equities research analysts expect that Precigen will post -0.32 earnings per share for the current fiscal year.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.